(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.16%) $0.928
(0.26%) $10.87
(-0.04%) $0.792
(-0.18%) $92.41
Live Chart Being Loaded With Signals
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases...
Stats | |
---|---|
Today's Volume | 9 692.00 |
Average Volume | 14 067.00 |
Market Cap | 4.00B |
EPS | €0 ( 2024-03-14 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 45.40 |
ATR14 | €0.0910 (0.10%) |
Volume Correlation
Financiere de Tubize SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Financiere de Tubize SA Correlation - Currency/Commodity
Financiere de Tubize SA Financials
Annual | 2022 |
Revenue: | €8 151.00 |
Gross Profit: | €-1.82M (-22 327.55 %) |
EPS: | €3.91 |
Q2 | 2023 |
Revenue: | €0 |
Gross Profit: | €0 (0.00 %) |
EPS: | €2.05 |
Q4 | 2022 |
Revenue: | €8 151.00 |
Gross Profit: | €-1.12M (-13 715.11 %) |
EPS: | €-1.330 |
Q2 | 2022 |
Revenue: | €0 |
Gross Profit: | €0 (0.00 %) |
EPS: | €3.25 |
Financial Reports:
No articles found.
Financiere de Tubize SA
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators